आधिकारिक वित्तीय विवरणों से राजस्व, लाभ और नकदी प्रवाह का इतिहास.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients.
इंटरैक्टिव चार्ट और पूर्ण वित्तीय विवरण देखें → वैल्यूएशन मॉडल (DCF) →
| आय विवरण | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| कुल राजस्व | $30.5B | $29.4B | $28.8B | $27.1B | $27.3B | $27.3B | $24.7B | $22.4B | $22.1B | $26.1B | $30.4B | $32.6B | $24.9B | $11.2B | $9.7B | $8.4B | $7.9B | $7.0B | $5.3B | $4.2B | $3.0B |
| सकल लाभ | $24.2B | $23.2B | $22.5B | $27.1B | $21.6B | $20.7B | $20.1B | $17.8B | $17.3B | $21.7B | $26.1B | $28.6B | $21.1B | $8.3B | $7.2B | $6.3B | $6.1B | $5.4B | $4.2B | $3.5B | $2.6B |
| सकल मार्जिन % | 79.6% | 78.8% | 78.3% | 100.0% | 79.3% | 75.8% | 81.5% | 79.2% | 78.1% | 83.3% | 86.0% | 87.7% | 84.8% | 74.5% | 74.5% | 74.7% | 76.5% | 77.2% | 78.9% | 81.8% | 85.7% |
| परिचालन लाभ (EBIT) | ($1.4B) | $11.7B | $1.7B | $7.6B | $7.3B | $9.9B | $4.1B | $4.3B | $8.2B | $14.1B | $17.6B | $22.2B | $15.3B | $4.5B | $4.0B | $3.8B | $4.0B | $3.5B | $2.7B | $2.2B | ($759M) |
| परिचालन मार्जिन % | -4.5% | 39.7% | 5.8% | 28.1% | 26.9% | 36.3% | 16.5% | 19.1% | 37.1% | 54.1% | 58.0% | 68.0% | 61.3% | 40.4% | 41.3% | 45.2% | 49.8% | 50.3% | 50.2% | 51.2% | -25.1% |
| शुद्ध लाभ | ($3.2B) | $8.5B | $480M | $5.7B | $4.6B | $6.2B | $123M | $5.4B | $5.5B | $4.6B | $13.5B | $18.1B | $12.1B | $3.1B | $2.6B | $2.8B | $2.9B | $2.6B | $2.0B | $1.6B | ($1.2B) |
| शुद्ध मार्जिन % | -10.6% | 28.9% | 1.7% | 20.9% | 16.8% | 22.8% | 0.5% | 24.0% | 24.6% | 17.7% | 44.4% | 55.5% | 48.6% | 27.5% | 26.7% | 33.4% | 36.5% | 37.6% | 37.1% | 38.2% | -39.3% |
| EBITDA | $1.1B | $13.6B | $4.4B | $7.6B | $8.9B | $11.3B | $4.1B | $7.6B | $10.3B | $15.9B | $19.2B | $23.4B | $16.3B | $4.9B | $4.3B | $4.2B | $4.3B | $3.8B | $2.9B | $2.2B | $1.7B |
| प्रति शेयर आय (EPS) | $-2.66 | $6.78 | $0.38 | $4.50 | $3.64 | $4.93 | $0.10 | $4.22 | $4.17 | $3.51 | $9.94 | $11.91 | $7.35 | $1.81 | $1.64 | $1.77 | $1.66 | $1.41 | $1.03 | $0.84 | $-0.65 |
| बकाया शेयर (मिलियन) | 1,243M | 1,255M | 1,255M | 1,258M | 1,262M | 1,262M | 1,263M | 1,277M | 1,308M | 1,319M | 1,358M | 1,521M | 1,647M | 1,695M | 1,583M | 1,580M | 1,747M | 1,868M | 1,918M | 1,929M | 1,836M |
स्रोत: कंपनी की सार्वजनिक रिपोर्टें (SEC). किसी भी आँकड़े पर भरोसा करने से पहले SEC EDGAR पर उसकी पुष्टि करें.
बैलेंस शीट, नकदी प्रवाह, तिमाही आँकड़े और सभी वित्तीय अनुपात GILD के इंटरैक्टिव व्यूअर में उपलब्ध हैं. /companies/us/GILD
इस वेबसाइट की जानकारी केवल शैक्षिक और सूचनात्मक उद्देश्यों के लिए है और निवेश सलाह नहीं है. कोई मूल्य लक्ष्य या सिफ़ारिश प्रकाशित नहीं की जाती.
About TickerBase · Data methodology & sources · Privacy · Terms